Skip to Main Content

Top of the morning, and a fine one, it is. The sun is trying to break through clouds hovering over the Pharmalot campus, where the shortest person is sleeping in and the official mascot is enjoying a play date with a neighborhood friend. As for us, we are engaged in the usual ritual of brewing delicious cups of stimulation in the cafeteria. Our choice today is the aromatic French vanilla. Feel free to join us, or grab a bottle of water, if you prefer. Meanwhile, here is the latest line up of items of interest. We hope your journey is smooth, insightful, and productive. And as always, do keep in touch. We relish saucy tips and secret dossiers. …

Biogen (BIIB) expects to begin a large clinical trial next May to confirm the benefits of its Alzheimer’s treatment, pending clearance from the U.S. Food and Drug Administration, STAT writes. The trial, which was a condition of agency approval, could answer some outstanding questions that have kept many neurologists from prescribing the drug, but it will be years before the company has data to show. The study will enroll more than 1,300 patients with early-stage Alzheimer’s from the U.S. and internationally, comparing Aduhelm to placebo over the course of 18 months. Other details about the trial design, including endpoints, are not being disclosed at this time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment